Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Daniel P Barboriak"'
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundProgressive enhancement predicted poor survival in ACRIN 6677/RTOG 0625, a multi-center trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma, but pseudoresponse likely limited enhancement-based survival prognostica
Externí odkaz:
https://doaj.org/article/e617ec5df0b8426884a2d978ad1992ed
Autor:
David A. Mankoff, Daniel P. Barboriak, A. Gregory Sorensen, Eva-Maria Ratai, Benjamin M. Ellingson, Edward A. Eikman, Lale Kostakoglu, Akiva Mintz, Kathleen M. Schmainda, Melissa Prah, Erin Greco, Lucy Hanna, Mark Muzi, James R. Fink, Zheng Zhang, Elizabeth R. Gerstner
Purpose: Structural and functional alterations in tumor vasculature are thought to contribute to tumor hypoxia which is a primary driver of malignancy through its negative impact on the efficacy of radiation, immune surveillance, apoptosis, genomic s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::683e1253757de96785d22b07f65d76d2
https://doi.org/10.1158/1078-0432.c.6524310.v1
https://doi.org/10.1158/1078-0432.c.6524310.v1
Autor:
David A. Mankoff, Daniel P. Barboriak, A. Gregory Sorensen, Eva-Maria Ratai, Benjamin M. Ellingson, Edward A. Eikman, Lale Kostakoglu, Akiva Mintz, Kathleen M. Schmainda, Melissa Prah, Erin Greco, Lucy Hanna, Mark Muzi, James R. Fink, Zheng Zhang, Elizabeth R. Gerstner
Supplemental Table 1: Participating centers that enrolled patients; Supplemental Table 2: Serial FMISO PET Imaging.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8436f1655db0bede1eaeb4f6a8d1c061
https://doi.org/10.1158/1078-0432.22459785
https://doi.org/10.1158/1078-0432.22459785
Autor:
Melissa Prah, Daniel P. Barboriak, Kathleen M. Schmainda, Eunhee Kim, Jerrold L. Boxerman, Helga S. Marques
Publikováno v:
Neuro Oncol
Background In Radiation Therapy Oncology Group (RTOG) 0825, a phase III trial of standard therapy with bevacizumab or without (placebo) in newly diagnosed glioblastoma, 44 patients underwent dynamic contrast enhanced (DCE) and/or dynamic susceptibili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83da1f29b7aa57957f09aea7ca3e201a
https://doi.org/10.1093/neuonc/noaa167
https://doi.org/10.1093/neuonc/noaa167
Autor:
Daniel P. Barboriak, Pinar Gumus Balikcioglu, Robert Benjamin, Nancie MacIver, Grace Hendrix, Herbert E. Fuchs
Publikováno v:
Journal of the Endocrine Society
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5934ae264fadce1ce6fbe91334d44e87
https://doi.org/10.1210/jendso/bvab160
https://doi.org/10.1210/jendso/bvab160
Autor:
Martin J. van den Bent, Lalitha K. Shankar, Marion Smits, Wolfgang Wick, Timothy F. Cloughesy, Mark R. Gilbert, W. K. Al Yung, Jayashree Kalpathy-Cramer, Susan M. Chang, Evanthia Galanis, C. Chad Quarles, Patrick Y. Wen, Paula M. Jacobs, Raymond Huang, Elizabeth R. Gerstner, Michael Weller, Benjamin M. Ellingson, Kathleen M. Schmainda, Timothy J. Kaufmann, Jerrold L. Boxerman, Caroline Chung, Daniel P. Barboriak, Bradley J. Erickson, Bruce R. Rosen, Leland S. Hu
Publikováno v:
Neuro Oncol
Neuro-Oncology, 22(9), 1262-1275. Oxford University Press
Neuro-Oncology, 22(9), 1262-1275. Oxford University Press
Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multicenter trials. Recently, the DSC-MRI Standardization Subcommitt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95798f30a3fd2f56ccf9c82555766641
https://hdl.handle.net/1765/133601
https://hdl.handle.net/1765/133601
Autor:
Christina Tsien, Jerrold L. Boxerman, Evanthia Galanis, Terry C. Burns, Nan Lin, Caroline Chung, Michael Weller, Patrick Y. Wen, Benjamin M. Ellingson, Daniel P. Barboriak, Paul D. Brown, Ian F. Parney, Elizabeth R. Gerstner, Lalitha K. Shankar, Timothy J. Kaufmann, Raymond Y. Huang, Martin J. van den Bent, Marion Smits, Gavin P. Dunn, Priscilla K. Brastianos
Publikováno v:
Neuro-Oncology, 22(6), 757-772. Oxford University Press
Neuro-oncology, vol 22, iss 6
Neuro Oncol
Neuro-oncology, vol 22, iss 6
Neuro Oncol
A recent meeting was held on March 22, 2019, among the FDA, clinical scientists, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocacy groups to discuss challenges and potential solutions for increasing develo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fee5e807b3d9c87a4a51998918a7b36
https://doi.org/10.1093/neuonc/noaa030
https://doi.org/10.1093/neuonc/noaa030
Autor:
Yair Safriel, Zheng Zhang, Mark R. Gilbert, Ronald L. Wolf, Jerrold L. Boxerman, Daniel P. Barboriak, Jeffrey M. Rogg, Suyash Mohan, A. Gregory Sorensen, Helga S. Marques
Publikováno v:
Neuro-Oncology. 20:1400-1410
BACKGROUND: ACRIN 6686/RTOG 0825 was a phase III trial of conventional chemoradiation plus adjuvant temozolomide with bevacizumab or without (placebo) in newly diagnosed glioblastoma. This study investigated whether changes in contrast-enhancing and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a96d56c76a3faa2b1047b2eb81748f8e
https://doi.org/10.1093/neuonc/noy049
https://doi.org/10.1093/neuonc/noy049
Publikováno v:
Neuro-Oncology Advances. 3:iv7-iv7
BACKGROUND Approximately 50% of patients with newly diagnosed high-grade glioma (HGG) develop progressive enhancement between their post-operative MRI scan and 12 weeks after radiation and temozolomide. Inter-reader variability on the assessment of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46aabd8f6909c9bacd396a38c22a670c
https://doi.org/10.1093/noajnl/vdab112.024
https://doi.org/10.1093/noajnl/vdab112.024
Autor:
David Schiff, Lawrence Kleinberg, Daniel P. Barboriak, Constantine Gatsonis, Jon A. Steingrimsson
Publikováno v:
Neuro-oncology Advances
Validated biomarkers that more accurately predict prognosis and/or measure disease burden in patients with high-grade gliomas would help triage which treatment strategies are most promising for evaluation in Phase III multicenter trials. Multicenter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc2812486a31d2b41577b3894cfca27f
https://doi.org/10.1093/noajnl/vdab112.006
https://doi.org/10.1093/noajnl/vdab112.006